Read More Pharma Industry News Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls Oxford Biomedica cut 2026 revenue guidance by £40m at midpoint. September results must show whether OXB’s setback is timing or something deeper. byVenkateshAugust 9, 2026